| Drug Name |
Fostamatinib |
| Drug ID |
BADD_D02499 |
| Description |
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].
Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] |
| Indications and Usage |
Fostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia (ITP) in patients who have had insufficient response to previous therapy [FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
B02BX09 |
| DrugBank ID |
DB12010
|
| KEGG ID |
D09347
|
| MeSH ID |
C523665
|
| PubChem ID |
11671467
|
| TTD Drug ID |
D0V8HJ
|
| NDC Product Code |
71332-001; 71332-002 |
| UNII |
SQ8A3S5101
|
| Synonyms |
fostamatinib | 2H-pyrido(3,2-b)-1,4-oxazin-3(4H)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)- | fostamatinib disodium anhydrous | 2H-pyrido(3,2-b)-1,4-oxazin-3(4H)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-, sodium salt (1:2) | R935788 sodium anhydrous | R-935788 sodium anhydrous | R788 sodium anhydrous | R-788 sodium anhydrous | fostamatinib disodium hydrate | fostamatinib disodium salt hexahydrate | R-788 sodium | R788 sodium | R788 sodium hydrate | R-935788 sodium hydrate | R935788 sodium hydrate | fostamatinib disodium | (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido(3,2-b)-1,4-oxazin-4-yl)methyl disodium phosphate hexahydrate | Tavalisse | R-788 sodium hydrate | R788 free acid | R-935788 free acid | R935788 free acid | R-788 free acid |
